Provision of IHC/ISH for Royal Marsden Hospital Chelsea and Sutton sites
What the buyer wrote
The Royal Marsden NHS Foundation Trust (RMH) is looking to refresh the immunohistochemistry (IHC) and in-situ hybridisation (ISH) provision for the department of Cellular Pathology at both the Sutton and Chelsea sites and to build greater capacity and resilience into the system enabling the department to cope with future workload increases, implement additional diagnostic tests, and provide enhanced turnaround times, whilst delivering a streamlined workflow, quality improvements and efficiency savings. The Cellular Pathology department is a national referral centre for cancer diagnostics with expertise in soft tissue sarcomas, haematological (as part of the Trust Specialist Integrated…
Details
- What the buyer calls it
- Provision of IHC/ISH for Royal Marsden Hospital Chelsea and Sutton sites
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Suitable for small firms
- The buyer says yes. What that is worth
- Work starts
- 1 Nov 2021
- Work ends
- 31 Oct 2026
- Kind of work
- Clinical and healthcare services
Who the buyer named
The buyer published a contact address on this notice.